Agilent Technologies is expanding nucleic acid API manufacturing capacity at its Boulder, Colorado, facility. Additionally, Agilent has purchased the assets of Dowpharma's Nucleic Acid Medicines business, the second disposal by Dowpharma in the same number of weeks. In Boulder Agilent is adding large-scale nucleic acid synthesis, purification and drying capacity. The new capacity is due on stream by the end of 2008.
Agilent
Thursday 8 May 2008
Agilent expands nucleic acid capacity, buys Dow technology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment